2019 CYIR Finalized
15 SUNDAY, MAY 19 INTERVENTIONAL PULMONOLOGY Mark R. Bowling, MD East Carolina University School of Medicine Pulmonary, Critical Care and Sleep Medicine Greenville, NC INTERVENTIONAL PULMONOLOGY TREATMENT OF EMPHYSEMA Criner GJ, Sue R, Wright S, Dransfield M, Rivas-Perez H, Wiese T, Sciurba FC, Shah PL, Wahidi MM, de Oliveira G, Morrissey B, Cardoso PFG, Hays S, Majid A, Hsia, DW, Sung A, Jarad N, Kornaszewska M, Hazelrigg S, Krishna G, Armstrong B, Shargill NS, Slebos, DJ; for the LIBERATE Study Group. A multicenter randomized controlled trial of Zephyr Endobronchial Valve treatment in heterogeneous emphysema (LIBERATE). Am J Respir Crit Care Med 2018 ; 198:1151–1164. Summary Previous studies have demonstrated that the treatment of severe emphysema with Endobronchial Valve (EBV) has not resulted in clinically meaningful changes compared to the standard of care (SOC). Post hoc analysis has identified that those patients with no collateral ventilation to the ipsilateral adjacent lobes and complete lobar occlusion with intact fissures responded best to the EBV therapy. In this multi- center, randomized, controlled trial, the effectiveness and safety of the Zephyr® EBV (pulmonx Redwood City CA) in the treatment of patients with heterogeneous emphysema and no collateral ventilation was evaluated. A total of 190 subjects were enrolled with a 2:1 randomization to either EBV with (SOC) (n=128) versus SOC alone (n=62). At 12 months, 47.7% of the EBV/SOC group and 16.8% SOC subjects had a change in FEV1 greater than or equal to 15% (P < 0.001). The EBV/SOC group also had significant changes in FEV1=0.106 L (P < 0.001), 6-minute-walk dis- tance=+39.31 m (P = 0.002), and St. George’s Respiratory Questionnaire=-7.05 points (P = 0.004); Pneumothorax was the most common serious adverse event in the treatment period (procedure to 45 days) occuring in 34/128 (26.6%) of EBV subjects. Comments 1. The LIBERATE trial demonstrated that patients with heteroge- neous emphysema and no collateral ventilation had clinically significant benefits in quality of life, lung function, and exercise tolerance at 12 months when treated with the Zephyr® EBV. 2. Compared to the National Emphysema Treatment Trial (NETT) those patients that responded to the EBV therapy had a 20% wider range of lung function and exercise tolerance than those patients that responded in the NETT study. 3. The pneumothorax rate was similar to previous trials and did seem to have adverse effects on clinical outcomes. 4. Unlike the NETT trial where those patients that responded best to lung volumes reduction surgery where those with low exer- cise tolerance as determined by baseline six-minute walk test 5. In patients with severe emphysema that are not candi- dates for lung volume reduction surgery or INTERVENTIONAL PULMONOLOGY, EBV is a safe and practical treatment option. NAVIGATIONAL BRONCHOSCOPY Folch EE, Pritchett M, Nead M, Bowling MR, Murgu SD, Krimsky WS, Murillo BA, LeMense GP, Minnich DJ, Bansal S, Ellis BQ, Mahajan AK, Gildea TR, Bechara RI, Sztejman E, Flandes J, Rickman OB, Benzaquen S, Hogarth KD, Linden PA, Wahidi MM, Mattingley JS, Hood KL, lin H, Wolvers JJ, Khandhar SJ; for the NAVIGATE Study Investigators. Electromagnetic Navigation Bronchoscopy for Peripheral Pulmonary Lesions: One-Year Results of the Prospective, Multicenter NAVIGATE Study. Journal of Thoracic Oncology 2018. Vol. 14 No. 3: 445-458 Summary The NAVIGATE trial is a prospective, multicenter, global, cohort study evaluating the safety and utility of electromag- netic navigational bronchoscopy [(ENB) superDimension™ navigation system] in the management of peripheral lung lesions. In the United States 1,215 consecutive subjects at 29 sites were enrolled and a 1-year interim analysis is reported. Among 1,157 subjects undergoing ENB guided biopsy: 94% (1092 of 1157) had navigation completed and tissue obtained, dye marking in 23, fiducial marker placement in 258, and lymph node sampling in 463 [96% with linear endobronchial ultrasound (EBUS)]. The majority (96%) of the subjects had at least 2 procedures performed during one anesthetic event (i.e. fiducial placement, medi- astinal staging, and biopsy of the peripheral lesion). Follow- up was completed in 80% of subjects at 12 months. The tissue diagnostic yield was 73%, with a reported sensitivity (69%), specificity (100%), positive predictive value (100%), and negative predictive value (56%) for malignancy. ENB related Common Terminology Criteria for Adverse Events grade 2 or higher were 2.9 % pneumothorax (requiring chest tube placement and/or hospital admission) and 1.5 % for bronchopulmonary hemorrhage. Grade 4 respiratory failure was 0.7%. The median lesion size was 20.0 mm.
Made with FlippingBook
RkJQdWJsaXNoZXIy MTM1ODMw